Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Cornelia Braicu & Claudia Gherman. (2013) Epigallocatechin gallate induce cell death and apoptosis in triple negative breast cancer cells Hs578T. Journal of Drug Targeting 21:3, pages 250-256.
Read now
Read now
Articles from other publishers (22)
Ashwathi Vijayalekha, Prathibha Sivaprakasam, Suresh Kumar Anandasadagopan, Ashok Kumar Kumar Pandurangan & Tamilselvi Alagumuthu. 2022. Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics. Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics
1
26
.
Sean A. Piwarski, Chelsea Thompson, Ateeq R. Chaudhry, James Denvir, Donald A. Primerano, Jun Fan & Travis B. Salisbury. (2020) The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells. Biochemical Pharmacology 174, pages 113845.
Crossref
Crossref
Xingjie Gao, Jing Wang, Meiqi Li, Jia Wang, Jian Lv, Lu Zhang, Caifeng Sun, Jiamei Ji, Wenbo Yang, Zinan Zhao & Weifeng Mao. (2019) Berberine attenuates XRCC1‐mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. Journal of Cellular and Molecular Medicine 23:10, pages 6797-6804.
Crossref
Crossref
Haipeng Zhang, Na Yu, Yan Chen, Kaowen Yan & Xiaozhen Wang. (2019) Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1‐deficient breast cancer cells to PARP1 inhibition. Journal of Cellular Biochemistry 120:8, pages 13037-13045.
Crossref
Crossref
Gamze Guney Eskiler, Gulsah Cecener, Unal Egeli & Berrin Tunca. (2018)
Triple negative breast cancer: new therapeutic approaches and
BRCA
status
. APMIS 126:5, pages 371-379.
Crossref
Crossref
Yuwan Zhao, Zuolei Jing, Jian Lv, Zhiwei Zhang, Jintao Lin, Xuejiao Cao, Zinan Zhao, Pixu Liu & Weifeng Mao. (2017) Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo. Biomedicine & Pharmacotherapy 95, pages 18-24.
Crossref
Crossref
Karolina Tecza, Jolanta Pamula-Pilat, Joanna Lanuszewska & Ewa Grzybowska. (2016) Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 7:41, pages 66790-66808.
Crossref
Crossref
Siker Kimbung, Anikó Kovács, Anna Danielsson, Pär-Ola Bendahl, Kristina Lövgren, Marianne Frostvik Stolt, Nicholas P. Tobin, Linda Lindström, Jonas Bergh, Zakaria Einbeigi, Mårten Fernö, Thomas Hatschek & Ingrid Hedenfalk. (2015) Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget 6:32, pages 33306-33318.
Crossref
Crossref
Tomi Akinyemiju, Justin Xavier Moore & Sean F. Altekruse. (2015) Breast cancer survival in African-American women by hormone receptor subtypes. Breast Cancer Research and Treatment 153:1, pages 211-218.
Crossref
Crossref
Yuping Liu, Pingting Zhu, Yingyu Wang, Zhonghong Wei, Li Tao, Zhijie Zhu, Xiaobo Sheng, Siliang Wang, Junshan Ruan, Zhaoguo Liu, Yuzhu Cao, Yunlong Shan, Lihua Sun, Aiyun Wang, Wenxing Chen & Yin Lu. (2015) Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling Pathways. PLOS ONE 10:4, pages e0123781.
Crossref
Crossref
Yasmin Turkman, Adomah Sakibia Opong, Lyndsay Harris & M. Knobf. (2015) Biologic, Demographic, and Social Factors Affecting Triple Negative Breast Cancer Outcomes. Clinical Journal of Oncology Nursing 19:1, pages 62-67.
Crossref
Crossref
Aruna S. Jaiswal, Dimitri Hirsch-Weil, Erick R. Proulx, Sukwon Hong & Satya Narayan. (2014) Anti-tumor activity of novel biisoquinoline derivatives against breast cancers. Bioorganic & Medicinal Chemistry Letters 24:20, pages 4850-4853.
Crossref
Crossref
Roxana Chiorean, Cornelia Braicu & Ioana Berindan-Neagoe. (2013) Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?. The Breast 22:6, pages 1026-1033.
Crossref
Crossref
Tyler J. W. Robinson, Jeff C. Liu, Frederick Vizeacoumar, Thomas Sun, Neil Maclean, Sean E. Egan, Aaron D. Schimmer, Alessandro Datti & Eldad Zacksenhaus. (2013) RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs. PLoS ONE 8:11, pages e78641.
Crossref
Crossref
Belinda J Cridge, Lesley Larsen & Rhonda J Rosengren. (2013) Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers. Oncology Discovery 1:1, pages 6.
Crossref
Crossref
Siker Kimbung, Ewa Biskup, Ida Johansson, Kristina Aaltonen, Astrid Ottosson-Wadlund, Sofia Gruvberger-Saal, Heather Cunliffe, Bengt Fadeel, Niklas Loman, Pontus Berglund & Ingrid Hedenfalk. (2012) Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters 319:2, pages 232-241.
Crossref
Crossref
Antony S. Tin, Shyam N. Sundar, Kalvin Q. Tran, Anna H. Park, Kevin M. Poindexter & Gary L. Firestone. (2012) Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anti-Cancer Drugs 23:4, pages 370-379.
Crossref
Crossref
Nilufer Bulut, Sercan Aksoy, Omer Dizdar, Didem S. Dede, Cagatay Arslan, Erkan Dogan, Ibrahim Gullu, Yavuz Ozisik & Kadri Altundag. (2010) Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Medical Oncology 28:S1, pages 75-79.
Crossref
Crossref
Erhan Ararat, Ilyas Sahin & Kadri Altundag. (2010) Aspirin intake may prevent metastasis in patients with triple-negative breast cancer. Medical Oncology 28:4, pages 1308-1310.
Crossref
Crossref
Fei-fei Zhou, Min Yan, Gui-fang Guo, Fang Wang, Hui-juan Qiu, Fei-meng Zheng, Yan Zhang, Qiang Liu, Xiao-feng Zhu & Liang-ping Xia. (2010) Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Medical Oncology 28:4, pages 1302-1307.
Crossref
Crossref
Richard S. Finn, Carmelo Bengala, Nuhad Ibrahim, Henri Roché, Joseph Sparano, Lewis C. Strauss, Justin Fairchild, Oumar Sy & Lori J. Goldstein. (2011) Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clinical Cancer Research 17:21, pages 6905-6913.
Crossref
Crossref
M. De Laurentiis, D. Cianniello, R. Caputo, B Stanzione, G. Arpino, S. Cinieri, V. Lorusso & S. De Placido. (2010) Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treatment Reviews 36, pages S80-S86.
Crossref
Crossref